Head & Neck CancerPhase 1EDS01 HNNCT07625423
Intratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent or Metastatic Head and Neck Tumors
A Phase 1 study testing EDS01 1.0×10^11 VP + Toripalimab, EDS01 5.0×10^11 VP + Toripalimab and EDS01 1.0×10^12 VP + Toripalimab in people with Head & Neck Cancer and Nasopharyngeal Cancinoma (NPC), run by West China Hospital at 1 site in China.
Trial summary
This single-center, Phase 1 study is evaluating the safety, tolerability, and preliminary antitumor activity of recombinant human endostatin adenovirus injection (EDS01) given by intratumoral injection in combination with toripalimab in adults with recurrent or metastatic head and neck tumors, including nasopharyngeal… Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Head & Neck Cancer, Nasopharyngeal Cancinoma (NPC)
- What is being tested?
- EDS01 1.0×10^11 VP + Toripalimab, EDS01 5.0×10^11 VP + Toripalimab and EDS01 1.0×10^12 VP + Toripalimab
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 9 participants
- Where
- 1 siteChina
- Study dates
- 27 Mar 2026to 30 Mar 2028
- Phase
- Phase 1
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults aged 18 to 65 years. Histologically or cytologically confirmed recurrent or metastatic head and neck tumor.
- Previously received at least 1 standard platinum-based systemic chemotherapy regimen for recurrent/metastatic disease, or had platinum-insensitive or platinum-intolerant disease after prior curative-intent treatment.
- Not suitable for surgery or radiotherapy. At least 1 target lesion suitable for intratumoral injection of recombinant human endostatin adenovirus injection.
- At least 1 measurable lesion with diameter ≥2 cm on imaging, according to RECIST version 1.1.
- No chemotherapy, radiotherapy, biologic antitumor therapy, or antiviral therapy within 4 weeks before enrollment.
- Estimated life expectancy of at least 12 weeks. ECOG performance status 0 to 1. Male or female participants of childbearing potential must agree to use reliable contraception during treatment and for at least 6 months after treatment.
- Recovery of prior treatment-related toxicities to NCI CTCAE grade 1 or baseline, with screening laboratory results within 1 week before enrollment meeting protocol requirements: ANC ≥1.5×10^9/L, platelet count ≥80×10^9/L, total bilirubin ≤1.5 × ULN, ALT and AST ≤2 × ULN, and coagulation parameters ≤1.25 × ULN.
- Willing and able to provide written informed consent.
Who cannot join
- Known allergy to the study drugs. Lesions involving major blood vessels or nerves and therefore unsuitable for local injection.
- Receiving radiotherapy to the study lesion at the same time. Prior anti-angiogenic therapy. Receiving immunosuppressive therapy or systemic corticosteroids for immunosuppressive purposes at a dose greater than prednisone 10 mg/day (or equivalent) within 2 weeks before enrollment.
- Active autoimmune disease or history of autoimmune disease. Congenital or acquired immunodeficiency. Risk of major nasopharyngeal hemorrhage or deep nasopharyngeal ulceration. Severe coagulation disorder or bleeding tendency. Severe uncontrolled medical disease or myocardial infarction within 3 months before enrollment.
- Acute infection. Pregnant or breastfeeding women. Any condition that, in the investigator's judgment, makes the participant unsuitable for enrollment.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
West China Hospital
Chengdu, China, 610041
Xuelei ma, 18708305692, drmaxuelei@gmail.com
About this study
Official title: A Phase I Clinical Trial of Intratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) Combined With Toripalimab for the Treatment of Recurrent or Metastatic Head and Neck Tumors
This single-center, Phase 1 study is evaluating the safety, tolerability, and preliminary antitumor activity of recombinant human endostatin adenovirus injection (EDS01) given by intratumoral injection in combination with toripalimab in adults with recurrent or metastatic head and neck tumors, including nasopharyngeal carcinoma, whose disease has progressed after platinum-based systemic therapy or who are not suitable for further platinum treatment.
A total of 9 participants will be enrolled in 3 planned dose groups of EDS01. EDS01 will be injected directly into an accessible tumor lesion on Days 0 and 7, and toripalimab 240 mg will be administered intravenously on Day 1 of each treatment cycle for up to 4 cycles, unless disease progression or unacceptable toxicity occurs. The study will evaluate treatment-related adverse events as well as preliminary efficacy outcomes, including tumor response, disease control, and time to progression, using clinical assessments, laboratory tests, imaging, and follow-up after treatment.
Read the detailed description
Patients with recurrent or metastatic head and neck tumors, including nasopharyngeal carcinoma, have limited treatment options after failure of platinum-based therapy. Anti-programmed cell death protein 1 (PD-1) therapy is an established later-line treatment option in this setting. EDS01 is a recombinant human endostatin adenovirus injection designed for intratumoral administration. By delivering the human endostatin gene into tumor cells, EDS01 is intended to support sustained local expression of endostatin and inhibit tumor angiogenesis. Head and neck lesions are often accessible for direct intratumoral injection and serial local assessment, which makes this disease setting suitable for evaluation of this approach. Prior early-phase clinical experience with EDS01 in advanced head and neck tumors showed that the main observed toxicities were fever, injection-site pain, and flu-like symptoms, without dose-limiting toxicity or serious adverse events at the studied dose levels, and preliminary antitumor activity was observed. These findings support further evaluation of EDS01 in combination with PD-1 blockade.
This single-center Phase 1 study is designed to evaluate the safety, tolerability, and preliminary antitumor activity of EDS01 in combination with toripalimab in adults with recurrent or metastatic head and neck tumors who have previously received platinum-based treatment or demonstrated platinum insensitivity or intolerance, and who have an injectable tumor lesion. The study will explore planned EDS01 dose levels in combination with fixed-dose toripalimab in order to characterize the safety profile of the regimen and identify whether the combination is feasible for further clinical development.
Study evaluations include clinical assessments, physical examinations, laboratory testing, and monitoring of adverse events and serious adverse events. Tumor response will be assessed radiographically according to RECIST version 1.1, including evaluation of objective response, disease control, and time to progression. Additional translational and exploratory assessments include anti-adenovirus antibody testing, serum endostatin measurement, and selected monitoring related to environmental shedding after intratumoral administration. After treatment, participants will enter follow-up and be assessed every 3 months until disease progression or death.
- Conditions
- Head & Neck Cancer, Nasopharyngeal Cancinoma (NPC)
- Being tested
- EDS01 1.0×10^11 VP + Toripalimab, EDS01 5.0×10^11 VP + Toripalimab, EDS01 1.0×10^12 VP + Toripalimab
- Keywords
- head and neck cancer, nasopharyngeal cancer, recombinant human endostatin adenovirus
- Medical subject headings
- Head and Neck Neoplasms, Nasopharyngeal Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
EDS01 1.0×10^11 VP + ToripalimabDrug
Recombinant human endostatin adenovirus injection (EDS01) is administered by intratumoral injection into an accessible tumor lesion on Days 0 and 7 of each 21-day cycle. Three planned dose levels are evaluated across study cohorts: 1.0×10^11 VP. Treatment may continue for up to 4 cycles unless disease progression or unacceptable toxicity occurs.
EDS01 5.0×10^11 VP + ToripalimabDrug
Recombinant human endostatin adenovirus injection (EDS01) is administered by intratumoral injection into an accessible tumor lesion on Days 0 and 7 of each 21-day cycle. Three planned dose levels are evaluated across study cohorts: 5.0×10^11 VP. Treatment may continue for up to 4 cycles unless disease progression or unacceptable toxicity occurs.
EDS01 1.0×10^12 VP + ToripalimabDrug
Recombinant human endostatin adenovirus injection (EDS01) is administered by intratumoral injection into an accessible tumor lesion on Days 0 and 7 of each 21-day cycle. Three planned dose levels are evaluated across study cohorts: 1.0×10^12 VP. Treatment may continue for up to 4 cycles unless disease progression or unacceptable toxicity occurs.
| Study group | Role | What they receive |
|---|---|---|
| EDS01 1.0×10^11 VP + Toripalimab | Experimental | Participants receive intratumoral EDS01 1.0×10^11 viral particles (VP) on Days 0 and 7 plus toripalimab 240 mg by intravenous infusion on Day 1 of each 21-day cycle. Treatment may continue for up to 4 cycles unless disease progression or unacceptable toxicity occurs. Receives: Drug: EDS01 1.0×10^11 VP + Toripalimab |
| EDS01 5.0×10^11 VP + Toripalimab | Experimental | Participants receive intratumoral EDS01 5.0×10^11 viral particles (VP) on Days 0 and 7 plus toripalimab 240 mg by intravenous infusion on Day 1 of each 21-day cycle. Treatment may continue for up to 4 cycles unless disease progression or unacceptable toxicity occurs. Receives: Drug: EDS01 5.0×10^11 VP + Toripalimab |
| EDS01 1.0×10^12 VP + Toripalimab | Experimental | Participants receive intratumoral EDS01 1.0×10^12 viral particles (VP) on Days 0 and 7 plus toripalimab 240 mg by intravenous infusion on Day 1 of each 21-day cycle. Treatment may continue for up to 4 cycles unless disease progression or unacceptable toxicity occurs. Receives: Drug: EDS01 1.0×10^12 VP + Toripalimab |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of adverse events (AEs) and serious adverse events (SAEs)
Number and percentage of participants with adverse events (AEs), serious adverse events (SAEs), treatment-related adverse events, and clinically significant abnormal laboratory findings. Adverse events will be graded according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC), version 4.0. Safety evaluation will also include physical examination findings and environmental shedding monitoring related to intratumoral administration of EDS01.
Measured: From signing informed consent through 1 month after the end of treatment (up to 16 weeks).
Secondary outcomes (4)
Objective response rate of target lesions
Proportion of participants with complete response (CR) or partial response (PR) in target lesions. Tumor response will be assessed according to RECIST version 1.1.
Measured: From baseline until disease progression or end of treatment, whichever occurs first (up to 3 years).
Disease control rate of target lesions
Proportion of participants with complete response (CR), partial response (PR), or stable disease (SD) in target lesions, assessed according to RECIST version 1.1.
Measured: From baseline until disease progression or end of treatment, whichever occurs first (up to 3 years).
Overall objective response rate of all lesions
Proportion of participants with complete response (CR) or partial response (PR) in overall lesions, assessed according to RECIST version 1.1.
Measured: From baseline until disease progression or end of treatment, whichever occurs first (up to 3 years).
Time to progression (TTP)
Time from enrollment to the first documented disease progression. Deaths before progression will be censored.
Measured: From enrollment until first documented disease progression; participants will be followed every 3 months after treatment until progression or death. Up to 3 years from enrollment.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Jun 2026
- Study start27 Mar 2026
- Primary completion30 Mar 2028 (estimated)
- Study completion30 Mar 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Head & Neck CancerStudies of the same condition, open and under way.
- More trials run by West China HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Model description
- This is a single-center, open-label, dose-escalation cohort study in which participants are assigned to 3 planned cohorts. All participants receive intratumoral EDS01 in combination with toripalimab, and the cohorts differ by the planned dose level of EDS01. The study is designed to characterize the safety and tolerability of the combination across prespecified dose cohorts in patients with recurrent or metastatic head and neck tumors.
- Masking
- None (open label)
- Enrolment
- 9 participants (estimated)
Sponsor and investigators
- Lead sponsor
- West China Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Xuelei Ma MD, West China Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07625423
- Sponsor's protocol ID
- 2025(395)
- Acronym
- EDS01 HN
- Status last verified
- Aug 2026
- First submitted
- 27 Mar 2026
- Last updated
- 2 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes